POUŽITÁ A DOPORUČENÁ LITERATURA

KAPITOLA 1

1. Bernardová J. Fototerapie ultrafialovým světlem. Dermatologie pro praxi. 2011;5(2):98–102.
2. Carmona-Cruz S, et al. The Human Skin Microbiome in Selected Cutaneous Diseases. Front Cell Infect Microbiol. 2022 Mar 7;12:834135
3. Ettler K. Foto(chemo)terapie v dermatologické léčbě. Česko-slovenská dermatologie. 2005;80(1):5–10.
4. EUROIMMUN Medizinische Labordiagnostika AG. ANA diagnostics using indirect immunofluorescence. Lübeck (Germany): EUROIMMUN Medizinische Labordiagnostika AG; 2020. (Brochure FA_1510_I_UK_B11). Dostupné z: https://www.euroimmun.com/documents/Indications/Autoimmunity/Rheumatology/ANA/FA_1510_I_UK_B.pdf
5. www.anapatterns.org ANA Patterns

KAPITOLA 2

1. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124(6):869–871.
2. Freites-Martinez A, Shapiro J, Goldfarb S, et al. CME Part 1: Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179–1196.
3. Hu Z, Bonifas JM, Beech J, Bench G, Shigihara T, Ogawa H, et al. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat Genet. 2000;24(1):61–65.
4. Chamli A, Zaouak A. Bowenoid papulosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023–. [aktualizováno 2022 Sep 12]. Dostupné z: https://www.ncbi.nlm.nih.gov/books/NBK539887/ (ncbi.nlm.nih.gov)
5. Irshad U, Puckett Y. Giant condylomata acuminata of Buschke and Löwenstein. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023–. [aktualizováno 2022 Aug 1]. Dostupné z: https://www.ncbi.nlm.nih.gov/books/NBK560714/ (ncbi.nlm.nih.gov)
6. Škapa P, Pichlík T, Pluta M, Halaška M, Robová H, Rob L, Tachezy R, Zámečník J. Klasifikace vulvárních prekanceróz pohledem patologa. Actual Gyn. 2014;6:26–32.

KAPITOLA 3

1. Dastychová E. Nežádoucí účinky extern obsahujících ketoprofen. Česko-slovenská dermatologie. 2000;75(2):51–55.
2. Ettler K. Fotoprotekce kůže: ochrana kůže před účinky ultrafialového záření. 1. vyd. Praha: Triton; 2004.
3. Fine JD. Epidermolysis bullosa. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. London: Mosby Elsevier; 2008. p. 457–466.
4. Jedličková H. Těhotenské dermatózy. Česko-slovenská dermatologie. 2007;82(4):173–183.
5. Malina L. Fotodermatózy. Praha: Maxdorf; 2005.
6. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
7. Porskjær Christensen L. Polyphenols and polyphenol-derived compounds from plants and contact dermatitis. In: Watson RR, Preedy VR, Zibadi S, editors. Polyphenols: Prevention and Treatment of Human Disease. 2nd ed. San Diego: Academic Press; 2018. p. 349–384.
8. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296–1304.

KAPITOLA 4

1. Alarcón-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed Connective Tissue Disease and Anti-Nuclear Antibodies. Amsterdam: Elsevier; 1987. p. 33–40.
2. Al-Khafaji AH. Toxic Shock Syndrome. In: Medscape [Internet]. Updated 2025 Jan 2. Dostupné z: https://emedicine.medscape.com/article/169177-overview. (emedicine.medscape.com)
3. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
4. Arenbergerová M, Pásek M, Arenberger P. Maligní melanom: diagnostika a léčba. 1. vyd. Praha: Maxdorf; 2023.
5. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–1159.
6. Bagherani N, Smoller BR. An overview of cutaneous T-cell lymphomas. F1000Res. 2016;5:F1000 Faculty Rev-1882.
7. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–153.
8. Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, Reutter J; ISSVD Terminology Committee. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. Obstet Gynecol. 2016;127(2):264–268.
9. Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72(2):239–245.
10. Darragh TM, Colgan TJ, Cox JT, et al.; Members of LAST Project Work Groups. The Lower Anogenital Squamous Terminology (LAST) Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136(10):1266–1297.

11. Denis D, Beneton N, Laribi K, Maillard H. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. Cancer Manag Res. 2019;11:2241–2251.
12. Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D, Kowalewski C, Jedlickova H, Kárpáti S, Marinovic B, Mimouni D, Uzun S, Yayli S, Hertl M, Borradori L. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015 Apr;172(4):867-77. doi: 10.1111/bjd.13717. PMID: 25827742.
13. Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and beyond. Ann Surg Oncol. 2018;25(8):2105–2110.
14. Honzíková K, Bučková H. Juvenilní dermatomyozitida – klinický případ. Čes-slov Derm. 2019;94(3):108–112.
15. Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96(10):1313–1328.
16. Jedličková H. Autoimunitní bulózní dermatózy. In: Benáková N, et al., eds. Moderní farmakoterapie v dermatologii. Praha: Maxdorf; 2020. s. 239–278.
17. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
18. Kirtschig G, Becker K, Günthert A, et al. Evidence-based (S3) guideline on (anogenital) lichen sclerosus. J Eur Acad Dermatol Venereol. 2015;29(10):e1–e43.
19. Kuhn A, Aberer E, Bata-Csörgő Z, Caproni M, Dreher A, Frances C, et al. S2k guideline for treatment of cutaneous lupus erythematosus—guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31(3):389–404.
20. Kulthanan K, Jiamton S, Boochangkool K, Jongjarearnprasert K. Angioedema: clinical and etiological aspects. Clin Dev Immunol. 2007;2007:26438.
21. Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome—Update 2023. Eur J Cancer. 2023;195:113343.
22. Leclair V, Lundberg IE. New myositis classification criteria—what we have learned since Bohan and Peter. Curr Rheumatol Rep. 2018;20(4):18.
23. Luger TA, Benesch D. Cutaneous manifestations. In: Smolen JS, Zielinski CC, editors. Systemic Lupus Erythematosus: Clinical and Experimental Aspects. Berlin/Heidelberg: Springer-Verlag; 1987. p. 227–250.
24. Masi AT, Rodnan GP, Medsger TA Jr, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581–590.
25. Navarini AA, Simpson MA, Borradori L, Yawalkar N, Schlapbach C. Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis. JAMA Dermatol. 2015;151(4):452–453.
26. Nemšovská J. Liekové hypersenzitívne reakcie: diagnostika a liečba (2. časť). Čes-slov Derm. 2019;94(5):192–202.
27. Nemšovská J. Liekové hypersenzitívne reakcie: klasifikácia a patogenéza (1. časť). Čes-slov Derm. 2019;94(3):99–106.
28. Pásek M. Maligní melanom. In: Benáková N, et al., editors. Moderní farmakoterapie v dermatologii. 2. vyd. Praha: Maxdorf; 2023. p. 429–458.
29. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686.
30. Petrů V. Doporučený postup léčby anafylaktické reakce – update 2019. Praha: Česká společnost alergologie a klinické imunologie ČLS JEP; 2019 [Internet]. Dostupné z: https://www.csaki.cz/soubory/stanoviska-a-doporuceni/8.-Doporuceny-postup-lecby-anafylaktickе-reakce.pdf.
31. Portál epidemiologie zhoubných novotvarů v ČR (SVOD). Epidemiologie zhoubného melanomu kůže (C43) [Internet]. Dostupné z: https://www.svod.cz/res/file/karty-diagnoz/c43.pdf. (svod.cz)
32. RegiSCAR. HSS/DRESS – Diseases of Interest. [Internet]. Dostupné z: https://www.regiscar.org/Diseases_HSS_DRESS.html.
33. Romano A, Atanaskovic-Markovic M, Barbaud A, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams—an EAACI position paper. Allergy. 2020;75(6):1300–1315.
34. Scleroderma Education Project. Scleroderma antibodies and clinical relevance. Scleroderma FAQ [Internet]. Dostupné z: https://sclerodermainfo.org/faq/scleroderma-antibodies/ (sclerodermainfo.org)
35. Sunderkötter CH, Zelger B, Chen KR, et al. Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheumatol. 2018;70(2):171–184.
36. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
37. Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome—Update 2017. Eur J Cancer. 2017;77:57–74.
38. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–2747.
39. Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. Int J Dermatol. 2019;58(5):538–542.
40. Vencovský J. Idiopatické zánětlivé myopatie – některé novější aspekty. Neurol praxi. 2020;21(6):477–484.
41. Vencovský J. Idiopatické zánětlivé myopatie – některé novější aspekty. Dermatol praxi. 2021;15(1):42–46.
42. WHO Classification of Tumours Editorial Board. Female genital tumours. 5th ed. (WHO Classification of Tumours; vol. 4). Lyon: International Agency for Research on Cancer; 2020. p. 419–434.
43. Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151–165.
44. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–1714.
45. Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2011;50(5):982–988.

KAPITOLA 5

1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S2k-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa (AWMF-Reg.-Nr. 013-012) – Langfassung. 2024 Aug 19 [Internet]. Dostupné z: https://register.awmf.org/assets/guidelines/013-012l_S2k_Therapie-Hidradenitis-suppurativa-Acne-inversa_2024-08.pdf.
2. Babaie F, Omraninava M, Gorabi AM, Khosrojerdi A, Aslani S, Yazdchi A, et al. Etiopathogenesis of psoriasis from genetic perspective: An updated review. Curr Genomics. 2022;23(3):163–174.
3. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993;186(1):23–31.

4. Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448–474.
5. Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, Thiboutot D. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):148–155.
6. Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index—A practical guide. Dermatitis. 2022;33(3):187–192.
7. Hnátková G, Hnátek L. Revize CEAP klasifikace z roku 2020 a její doporučení pro klinickou praxi. Prakt. flebol. 2022;1–4:1–72.
8. Hubka V, Čmoková A, Peano A, Větrovský T, Dobiáš R, Mallátová N, et al. Zoonotické dermatofytózy: klinický obraz, diagnostika, etiologie, léčba, epidemiologická situace u nás. Čes-slov Derm. 2018;93(6):208–235.
9. Hubka V, Čmoková A, Skořepová M, Mallátová N, Dobiášová S, Lysková P, et al. Současný vývoj v taxonomii dermatofytů a doporučení pro pojmenovávání klinicky významných druhů. Česko-slovenská dermatologie. 2014;89(4):151–165.
10. International Society for the Study of Vascular Anomalies (ISSVA). ISSVA Classification of Vascular Anomalies [Internet]. 2018 [aktualizováno 2025]. Dostupné z: https://www.issva.org/classification.
11. Kolek V, Žurková M, Lošťáková V. Sarkoidóza – nadále záhadné onemocnění. Vnitř Lék. 2017;63(11):807–814. [Internet]. Dostupné z: https://www.prolekare.cz/casopisy/vnitrni-lekarstvi/2017-11/sarkoidoza-nadale-zahadne-onemocneni-62534.
12. Machovcová A. Kontaktní dermatitidy – část II: epikutánní testy v současné praxi. Čes-slov Derm. 2016;91(5):207–221.
13. Nevoralová Z, Rulcová J, Benáková N. Obličejové dermatózy. 2. vyd. Praha: Mladá fronta; 2018.
14. Pichler WJ, Hausmann O. Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms. Int Arch Allergy Immunol. 2016;171(3-4):166–179.
15. Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74(8):1457–1471.
16. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–2673.
17. U.S. Department of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0—Quick Reference [Internet]. 2017 Nov 27. Dostupné z: https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf.
18. Vocanson M, Hennino A, Rozières A, Poyet G, Nicolas JF. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy. 2009;64(12):1699–1714.
19. Wilkinson SM, Gonçalo M, Aerts O, Badulici S, Dickel H, Gallo R, et al. The European baseline series and recommended additions: 2023. Contact Dermatitis. 2023;88(2):87–92.
20. Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al.; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744.
21. Yamamura Y, Nakashima C, Otsuka A. Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human. Front Med (Lausanne). 2024;11:1342176.

KAPITOLA 6

1. Garbe C, Husak R, Orfanos CE. HIV-associated dermatoses and their prevalence in 456 HIV-infected patients: relation to immune status and its importance as a diagnostic marker. Hautarzt. 1994; 45(9): 623–9.

KAPITOLA 7

1. Centers for Disease Control and Prevention (CDC). Schistosomiasis [Internet]. Updated 2024 Mar 4. Dostupné z: https://www.cdc.gov/schistosomiasis/
2. Dusilová Sulková S. Komentář k článku „Kalcifylaxe". Postgraduální nefrologie. 2011;9(2):29.
3. Errami M, Margulis V, Huerta S. Renal cell carcinoma metastatic to the scalp. Rare Tumors. 2016;8(4):6400.
4. Fencl F, Šibíková M, David J. Syndrom multisystémové zánětlivé odpovědi asociovaný s COVID-19 u dětí (PIMS-TS). Doporučený postup České pediatrické společnosti ČLS JEP [Internet]. 2020 Dec 8. Dostupné z: https://www.pediatrics.cz/content/uploads/2020/12/pims-ts-finalni-verze-8_12_2020.pdf
5. Frey T, Barták P. Acanthoma supratrochantericum. Cutis. 1992;49(6):412–416.
6. Jehlička P, Lád V, Sedláček D. Kawasakiho syndrom. Pediatr. praxi. 2008;9(1):12–14.
7. Kelblerová A. Infekční exantémová onemocnění v dětském věku. Pediatr. praxi. 2009;10(3):176–179.
8. Kouřilová P, Hogg KG, Kolářová L, Mountford AP. Cercarial dermatitis caused by bird schistosomes comprises both immediate and late phase cutaneous hypersensitivity reactions. J Immunol. 2004;172(6):3766–3774.
9. Šafránek R. Kalcifylaxe. Postgraduální nefrologie. 2011;9(2):17–32.
10. Wikipedie. Cerkáriová dermatitida [Internet]. Dostupné z: https://cs.wikipedia.org/wiki/Cerk%C3%A1riov%C3%A1_dermatitida

KAPITOLA 8

1. https://szu.gov.cz/temata-zdravi-a-bezpecnosti/a-z-infekce/s/syfilis-prijice-lues/syfilis-tradicni-choroba-soucasny-problem-ii/
2. Resl V., Zákoucká H. Metodický návod k řešení problematiky sexuálně přenosných infekcí v České republice (Věstník č. 12/2021 MZČR) Čes-slov Derm, 96, 2021, No. 6, p. 260–279
3. Šťáva Z, Jirásek L. Základy dermatologie a venerologie v tabulkách a schématech. Praha: SZD; 1957.
4. Zákoucká H. Sexuálně přenosné infekce (STI) v ČR – aktuální situace. Referátový výběr. 2021;4.

KAPITOLA 10

1. Evropská léková agentura. Cibinqo (abrocitinib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/cibinqo-epar-product-information_en.pdf.
2. Evropská léková agentura. Humira (adalimumab) – SmPC / EPAR [Internet]. Dostupné z: https://www.ema.europa.eu/en/medicines/human/EPAR/humira.

3. Evropská léková agentura. Lemtrada (alemtuzumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_en.pdf.
4. Evropská léková agentura. Otezla (apremilast) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/otezla-epar-product-information_en.pdf.
5. Evropská léková agentura. Bavencio (avelumab) – EPAR (SmPC v sekci Product information) [Internet]. Dostupné z: https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio.
6. Evropská léková agentura. Olumiant (baricitinib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf.
7. Evropská léková agentura. Bimzelx (bimekizumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf.
8. Evropská léková agentura. Mektovi (binimetinib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf. (ie.moalmanac.org)
9. Evropská léková agentura. Kyntheum (brodalumab) – EPAR (vč. Product information) [Internet]. Dostupné z: https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum.
10. Evropská léková agentura. Libtayo (cemiplimab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf.
11. Evropská léková agentura. Cimzia (certolizumab pegol) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf.
12. Evropská léková agentura. Cotellic (cobimetinib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf. (Merck.com)
13. Evropská léková agentura. Tafinlar (dabrafenib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf.
14. Evropská léková agentura. Sotyktu (deucravacitinib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/sotyktu-epar-product-information_en.pdf.
15. Evropská léková agentura. Dupixent (dupilumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf.
16. Evropská léková agentura. Braftovi (encorafenib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf.
17. Evropská léková agentura. Enbrel (etanercept) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf.
18. Evropská léková agentura. Tremfya (guselkumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf.
19. Evropská léková agentura. Remicade (infliximab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf.
20. Evropská léková agentura. Yervoy (ipilimumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf.
21. Evropská léková agentura. Taltz (ixekizumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf.
22. Evropská léková agentura. Ebglyss (lebrikizumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/ebglyss-epar-product-information_en.pdf.
23. Evropská léková agentura. Poteligeo (mogamulizumab) – EPAR (vč. Product information) [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/poteligeo-epar-product-information_en.pdf.
24. Evropská léková agentura. Opdivo (nivolumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf.
25. Evropská léková agentura. Xolair (omalizumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf.
26. Evropská léková agentura. Keytruda (pembrolizumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf.
27. Evropská léková agentura. Opdualag (nivolumab/relatlimab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf.
28. Evropská léková agentura. Skyrizi (risankizumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf.
29. Evropská léková agentura. Litfulo (ritlecitinib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/litfulo-epar-product-information_en.pdf. (Merck.com)
30. Evropská léková agentura. Cosentyx (secukinumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf.
31. Evropská léková agentura. Odomzo (sonidegib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf. (European Medicines Agency (EMA))
32. Evropská léková agentura. Ilumetri (tildrakizumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf.
33. Evropská léková agentura. Adtralza (tralokinumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf.
34. Evropská léková agentura. Mekinist (trametinib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf.
35. Evropská léková agentura. Rinvoq (upadacitinib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf.
36. Evropská léková agentura. Stelara (ustekinumab) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf.
37. Evropská léková agentura. Zelboraf (vemurafenib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf.
38. Evropská léková agentura. Erivedge (vismodegib) – SmPC [Internet]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf.
39. Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847.